The commercial platform for healthcare

Sell more. Waste less.

We help pharmaceutical and medical device sales teams find, target, and close the right accounts faster.

Real customer outcomes.

The numbers speak for themselves.

+106%

Increase in prospect engagement

42%

Conversion rate on prospect targeting

5 hrs

Saved per week per rep on prospect research

+23.6%

Monthly revenue uplift after switching to Rare.

Source: Rare.Monitor users 2025-2026.

Trusted by the best in the business

"The Rare. strength is a combination of large data samples, strong data analytics & insight generation capabilities and, importantly, ability to listen to the customer needs and give us clear options based on that. This makes Rare: a high quality thought partner."

Anton Petrov

Brand Director, L'Oreal

"I have worked with Rare.Monitor during my previous and current role. It has provided unparalleled access to market insights for both strategic planning and supporting my teams to expand their customer base. The team at Rare. are super responsive to feedback and provide excellent support to optimise the tools. We also use the data to support our existing clients with business planning by looking at their local competitive landscape to help them find new opportunities. I would have loved access to this when I was a sales rep, now I get to empower my team with high quality data and remove the time consuming task of hunting for new prospects on Google and Socials instead."

Natalie Colbourne

Director of Commercial Programmes and Strategy, Establishment Labs

"Their methodology was robust throughout and I was very impressed by their attention to detail and implementation plans for rollout to the broader team. I highly recommend partnering with the Rare: team!"

Isabel Diez-Sevilla

Business Insights & Analytics Manager, Daiichi Sankyo UK

"Proud to see SUNEKOS among the top 5 most mentioned injectable brands in the UK. A result that reflects the professionalism, perseverance, and scientific integrity that define our work every day at Professional Dietetics. Great Analysis!"

Tiziano Cameroni

C.E.O. & Co-Owner, Professional Dietetics

L'Oreal
Alibreo
MAP Health
NHS
The London Clinic
Galderma
Vivacy
Align Technology
Alma
Members of
  • MRS
  • ABPI
  • BHBIA

Find prospects. Track accounts. Close faster.

Rare.Monitor gives your commercial team one place to find new prospects, manage accounts, and track what's working, across over 160,000 UK and Ireland healthcare providers. Live market data and account management built into the same workflow, so your reps act on insight the moment they see it.

Find prospects. Track accounts. Close faster.

Three things commercial teams notice within the first month

Why RARE.

01

Built for commercial teams in private healthcare

Not a generic CRM, not a research subscription. Rare.Monitor mirrors how pharma and medical device teams actually work: targeting accounts, prioritising opportunities, reading the channel.

02

Live data, not last year's report

The provider dataset behind Rare.Monitor refreshes daily.

03

One source of truth

Prospecting, account management, and live market intelligence on UK private healthcare. No system-hopping between tools.

Ready to double your revenue?

Our clients have. Book a demo and we'll show you how Rare.Monitor helped one team increase rep revenue by 98%.

Latest

Insights

Bridgeport buys Obagi - is the distribution strategy the right one for targetting the UK market?
Market insights Read now

Bridgepoint buys Obagi: is the injectables-led UK strategy the right one?

Bridgepoint has added the leading UK medical-grade skincare brand to a portfolio that already includes Vivacy injectables, referencing these partnerships as a way to grow in the market. But there may be a headwind ahead. Rare. Monitor’s UK clinic data shows the cross-sell affinity sits closer with energy-based devices, rather than injectables.

9 June 2026

Featured image for the Rare anxiety report. Black ground with the predicted-vs-observed scatter from chart 02, named highlights for Southampton, Croydon, Wiltshire, Stoke-on-Trent, Knowsley, Enfield and Newham. Rare wordmark and Bold Blue accent.
Market insights Read now

Why anxiety doesn't track deprivation across English local authorities

Across 126 English local authorities, adult anxiety is only weakly correlated with deprivation. Rare's analysis shows where elevated anxiety concentrates, why deprivation-led service planning misses it, and what that means for commissioners, NHS providers and the private wellness market.

2 June 2026

Beyond the Prescription
Market insights Read now

Beyond the Prescription

Community pharmacy is rated good by 88% of patients in the 2025 GP Patient Survey, against 69.6% for GP practices. That structural eighteen-point gap is what makes pharmacy a credible destination for the consultation and clinical work NHS Pharmacy First is asking it to absorb. 2025 is the first full post-launch year and the data shows the channel doing what the policy intended, but along three distinct regional lines: South East for consultation, London for GP-routed referrals, North West for clinical services. South East referrals flow predominantly through 111 and A&E, not GPs.

26 May 2026